Sander I. van Leuven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sander I. van Leuven has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Amy S Major
Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center , Nashville, TN
2 shared publications- Caroline van Durme
Department of Rheumatology, Maastricht University Medical Centre+ , Maastricht
2 shared publications - Jacqueline Mj Lemmers
Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications - Michael T. Nurmohamed
Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands
2 shared publications - Robin Nijveldt
Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications Sjoerd Heslinga
Department of Rheumatology, St. Jansdal Hospital , Harderwijk
2 shared publications
Latest Publications
- 23 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Cardioprotective mechanisms and efficacy of colchicine, methotrexate, hydroxychloroquine, sulfasalazine and leflunomide in inflammatory rheumatic and musculoskeletal diseases (RMDs)
Chronic systemic inflammation contributes to the excess risk of atherosclerotic cardiovascular disease (ASCVD) in inflammatory rheumatic and musculoskeletal diseases (RMDs), raising the possibility that anti-inflammatory treatment may modify vascular risk. This review sought to critically address the mechanistic and clinical evidence for atheroprotection with colchicine and the commonly used conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) methotrexate, hydroxychloroquine, sulfasalazine and leflunomide. We performed a targeted narrative review of key experimental studies, randomized cardiovascular outcome trials, observational RMD cohorts and systematic reviews, prioritizing evidence directly relevant to ASCVD outcomes and cardiometabolic mechanisms. Colchicine has the strongest randomized evidence for reducing recurrent ASCVD events in patients with established coronary disease, with supportive observational data in gout. Methotrexate is associated with fewer cardiovascular events in rheumatoid arthritis (RA), whereas the CIRT trial was neutral in patients without inflammatory arthritis. Hydroxychloroquine has favourable lipid, glycaemic and antithrombotic effects and observational associations with lower cardiovascular risk in RA and systemic lupus erythematosus, but no definitive cardiovascular outcome trial. Evidence for sulfasalazine is limited and observational, and human data for leflunomide are conflicting. Cardiovascular benefit differs substantially between agents and is most convincing for colchicine in secondary prevention and for inflammation control with methotrexate in RA. Dedicated prospective trials in inflammatory RMD populations are needed before any csDMARD can be prescribed primarily for ASCVD prevention.
- 23 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Cardioprotective mechanisms and efficacy of colchicine, methotrexate, hydroxychloroquine, sulfasalazine and leflunomide in inflammatory rheumatic and musculoskeletal diseases (RMDs)
Chronic systemic inflammation contributes to the excess risk of atherosclerotic cardiovascular disease (ASCVD) in inflammatory rheumatic and musculoskeletal diseases (RMDs), raising the possibility that anti-inflammatory treatment may modify vascular risk. This review sought to critically address the mechanistic and clinical evidence for atheroprotection with colchicine and the commonly used conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) methotrexate, hydroxychloroquine, sulfasalazine and leflunomide. We performed a targeted narrative review of key experimental studies, randomized cardiovascular outcome trials, observational RMD cohorts and systematic reviews, prioritizing evidence directly relevant to ASCVD outcomes and cardiometabolic mechanisms. Colchicine has the strongest randomized evidence for reducing recurrent ASCVD events in patients with established coronary disease, with supportive observational data in gout. Methotrexate is associated with fewer cardiovascular events in rheumatoid arthritis (RA), whereas the CIRT trial was neutral in patients without inflammatory arthritis. Hydroxychloroquine has favourable lipid, glycaemic and antithrombotic effects and observational associations with lower cardiovascular risk in RA and systemic lupus erythematosus, but no definitive cardiovascular outcome trial. Evidence for sulfasalazine is limited and observational, and human data for leflunomide are conflicting. Cardiovascular benefit differs substantially between agents and is most convincing for colchicine in secondary prevention and for inflammation control with methotrexate in RA. Dedicated prospective trials in inflammatory RMD populations are needed before any csDMARD can be prescribed primarily for ASCVD prevention.
- 1 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Cardiorheumatology is ready for the limelight
- 1 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Cardiorheumatology is ready for the limelight
- Open Access
- 23 April 2026
- Published by MDPI AG in Gout, Urate, and Crystal Deposition Disease
- Vol. 4 (2) , 9
Hyperuricemia Beyond Gout: The Unknown Culprit in Rheumatic and Musculoskeletal Diseases
Hyperuricemia influences several aspects of the immune system. It enhances cytokine production by monocytes and activates neutrophils and natural killer cells. Within the adaptive immune system, hyperuricemia enhances antigen presentation, skews T helper cell differentiation toward the Th17 lineage and may also activate B cells. Beyond its established role in the pathogenesis of gout, hyperuricemia may therefore contribute to other rheumatic diseases. In this review, we summarize current evidence on the role of hyperuricemia in osteoarthritis, psoriatic arthritis, axial spondylarthritis, rheumatoid arthritis, systemic sclerosis, primary Sjögren’s disease and systemic lupus erythematosus. Available data do not support a causal role for hyperuricemia in the disease onset of osteoarthritis or rheumatoid arthritis. In contrast, hyperuricemia is associated with the development of psoriatic arthritis and may be linked to a more severe disease course. Small, predominantly cross-sectional studies further suggest a potentially adverse role of hyperuricemia in systemic sclerosis, Sjögren’s disease, and systemic lupus erythematosus. Across several rheumatic diseases, hyperuricemia is associated with cardiovascular disease, renal dysfunction and interstitial lung disease. However, both mechanistic and causal evidence remain limited, underscoring the need for more studies.
- 23 April 2026
- Published by MDPI AG in Gout, Urate, and Crystal Deposition Disease
- Vol. 4 (2) , 9
Open AccessHyperuricemia Beyond Gout: The Unknown Culprit in Rheumatic and Musculoskeletal Diseases
Hyperuricemia influences several aspects of the immune system. It enhances cytokine production by monocytes and activates neutrophils and natural killer cells. Within the adaptive immune system, hyperuricemia enhances antigen presentation, skews T helper cell differentiation toward the Th17 lineage and may also activate B cells. Beyond its established role in the pathogenesis of gout, hyperuricemia may therefore contribute to other rheumatic diseases. In this review, we summarize current evidence on the role of hyperuricemia in osteoarthritis, psoriatic arthritis, axial spondylarthritis, rheumatoid arthritis, systemic sclerosis, primary Sjögren’s disease and systemic lupus erythematosus. Available data do not support a causal role for hyperuricemia in the disease onset of osteoarthritis or rheumatoid arthritis. In contrast, hyperuricemia is associated with the development of psoriatic arthritis and may be linked to a more severe disease course. Small, predominantly cross-sectional studies further suggest a potentially adverse role of hyperuricemia in systemic sclerosis, Sjögren’s disease, and systemic lupus erythematosus. Across several rheumatic diseases, hyperuricemia is associated with cardiovascular disease, renal dysfunction and interstitial lung disease. However, both mechanistic and causal evidence remain limited, underscoring the need for more studies.
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1) , rkag015
Exploring cardiovascular risk management implementation in Dutch rheumatoid arthritis patients: insights from rheumatologists and patients
Objectives: To explore the implementation of cardiovascular risk management (CVRM) in Dutch RA patients from the perspective of rheumatologists and patients. Methods: An online survey was conducted among Dutch rheumatologists, rheumatology physician assistants (PAs) and RA patients. Healthcare providers completed a 37-item adapted version of the Determinants of Implementation Behavior Questionnaire to assess various aspects of CVRM implementation behaviour on a 7-point Likert scale. Simultaneously, a 13-item questionnaire was administered to RA patients to gather experiences related to CVRM. Data for both surveys were collected online between 23 September and 1 December 2024. Results: A total of 85 healthcare providers [93% rheumatologists, mean age 47.2 years (s.d. 8.8), 72% female] and 145 RA patients [mean age 58 years (s.d. 12.6), 89% female] completed the survey. Providers did not seem to lack (self-reported) knowledge on CVRM, yet significant implementation challenges were identified across several domains, including skills, professional roles and beliefs about capabilities. Time constraints, limited resources, insufficient financial support and the absence of local protocols were cited as major barriers. From the patient perspective, only 39% reported being informed about RA-related cardiovascular risks, mostly by rheumatologists. Rheumatologists frequently provided guidance on physical activity (21%), while general practitioners were more active in managing traditional cardiovascular risk factors, prescribing medications (23%) and offering self-management advice (16%). Conclusion: Our study highlights the main challenges in implementing CVRM in daily practice, indicating the need for the development of targeted strategies to overcome these barriers.
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1) , rkag015
Open AccessExploring cardiovascular risk management implementation in Dutch rheumatoid arthritis patients: insights from rheumatologists and patients
Objectives: To explore the implementation of cardiovascular risk management (CVRM) in Dutch RA patients from the perspective of rheumatologists and patients. Methods: An online survey was conducted among Dutch rheumatologists, rheumatology physician assistants (PAs) and RA patients. Healthcare providers completed a 37-item adapted version of the Determinants of Implementation Behavior Questionnaire to assess various aspects of CVRM implementation behaviour on a 7-point Likert scale. Simultaneously, a 13-item questionnaire was administered to RA patients to gather experiences related to CVRM. Data for both surveys were collected online between 23 September and 1 December 2024. Results: A total of 85 healthcare providers [93% rheumatologists, mean age 47.2 years (s.d. 8.8), 72% female] and 145 RA patients [mean age 58 years (s.d. 12.6), 89% female] completed the survey. Providers did not seem to lack (self-reported) knowledge on CVRM, yet significant implementation challenges were identified across several domains, including skills, professional roles and beliefs about capabilities. Time constraints, limited resources, insufficient financial support and the absence of local protocols were cited as major barriers. From the patient perspective, only 39% reported being informed about RA-related cardiovascular risks, mostly by rheumatologists. Rheumatologists frequently provided guidance on physical activity (21%), while general practitioners were more active in managing traditional cardiovascular risk factors, prescribing medications (23%) and offering self-management advice (16%). Conclusion: Our study highlights the main challenges in implementing CVRM in daily practice, indicating the need for the development of targeted strategies to overcome these barriers.
- Open Access
- 1 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1187-1188
How Representative Are Data From Clinical Trials in Axial Spondyloarthritis for Women?
The interesting data described in this issue of The Journal of Rheumatology, in the study by Choufani et al entitled "Diversity in axial spondyloarthritis drug trials: Enrollment by sex, race, ethnicity, and geographic region,"1 including trials between 2000 and 2023, should be viewed from a historical perspective. In the case of radiographic (r-) axial spondyloarthritis (axSpA), treatment options were very limited (predominantly to nonsteroidal antirheumatic drugs) for a long period of time.
- 1 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1187-1188
Open AccessHow Representative Are Data From Clinical Trials in Axial Spondyloarthritis for Women?
The interesting data described in this issue of The Journal of Rheumatology, in the study by Choufani et al entitled "Diversity in axial spondyloarthritis drug trials: Enrollment by sex, race, ethnicity, and geographic region,"1 including trials between 2000 and 2023, should be viewed from a historical perspective. In the case of radiographic (r-) axial spondyloarthritis (axSpA), treatment options were very limited (predominantly to nonsteroidal antirheumatic drugs) for a long period of time.
- Open Access
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (2) , rkaf048
Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion
Patients with systemic lupus erythematosus (SLE) have increased risk of developing atherosclerotic cardiovascular disease (ASCVD). This excessive risk starts to accumulate during the earliest stages of SLE. ASCVD in SLE is associated with an adverse outcome. SLE-enhanced atherogenesis is most likely the consequence of a complex interplay between traditional risk factors and chronic auto-immune inflammation. This underscores the importance of conscientious management of traditional risk factors as well as maintaining low SLE disease activity. Shared immune pathways in SLE and ASCVD can affect the vascular biology of the atherosclerotic process in patients with SLE. In this review, we will discuss how the ASCVD risk evolves during the SLE disease course, and we consider whether patients with SLE are prone to developing superficial erosion of atherosclerotic plaques. This is highly relevant as pilot studies in the general population suggest antithrombotic therapy without stenting could be the better therapeutic approach in patients with plaque erosion.
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (2) , rkaf048
Open AccessAtherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion
Patients with systemic lupus erythematosus (SLE) have increased risk of developing atherosclerotic cardiovascular disease (ASCVD). This excessive risk starts to accumulate during the earliest stages of SLE. ASCVD in SLE is associated with an adverse outcome. SLE-enhanced atherogenesis is most likely the consequence of a complex interplay between traditional risk factors and chronic auto-immune inflammation. This underscores the importance of conscientious management of traditional risk factors as well as maintaining low SLE disease activity. Shared immune pathways in SLE and ASCVD can affect the vascular biology of the atherosclerotic process in patients with SLE. In this review, we will discuss how the ASCVD risk evolves during the SLE disease course, and we consider whether patients with SLE are prone to developing superficial erosion of atherosclerotic plaques. This is highly relevant as pilot studies in the general population suggest antithrombotic therapy without stenting could be the better therapeutic approach in patients with plaque erosion.
- Open Access
- 29 March 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (9) , 2525-2534
Systemic sclerosis-associated pulmonary arterial hypertension is characterized by a distinct peripheral T helper cell profile
Systemic sclerosis (SSc) is characterized by multiple clinical manifestations. Vasculopathy is a main disease hallmark and ranges in severity from an exacerbated Raynaud phenomenon to pulmonary arterial hypertension (PAH). The potential involvement of the immune system in SSc-associated vascular abnormalities is not clear. Here, we set out to study SSc-related immune parameters and determine whether and which peripheral T cell subsets associate with vascular severity in SSc patients. Peripheral blood and clinical data were collected from 30 SSc patients, 5 patients with idiopathic PAH and 15 age and sex-matched healthy donors (HD). In this cross-sectional cohort, SSc patients with PAH (n = 15) were matched for their age, sex and medication with SSc patients with no signs of PAH (n = 15). Lymphocyte subsets were quantified by multi-colour flow cytometry. SSc patients exhibited elevated percentages of T peripheral helper cells (Tph), CD4+GZMB+ T cells and decreased levels of Th1 cells compared with HD. Increased presence of both CD4+ and CD8+ exhausted-like (CD28−) T cells, characterized by raised cytokine and cytotoxic signature, was also observed in SSc compared with HD blood. Furthermore, IL-4 expressing CD4+CD8+ T cells were significantly increased in SSc peripheral blood. Interestingly, the presence of PAH in SSc was accompanied by a distinct T helper profile, characterized by raised percentages of Th17 and Tph cells. SSc patients with severe vasculopathy (presence of PAH) exhibited a distinct T cell profile, suggesting a potential role of auto-immune inflammation in SSc vascular complications.
- 29 March 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (9) , 2525-2534
Open AccessSystemic sclerosis-associated pulmonary arterial hypertension is characterized by a distinct peripheral T helper cell profile
Systemic sclerosis (SSc) is characterized by multiple clinical manifestations. Vasculopathy is a main disease hallmark and ranges in severity from an exacerbated Raynaud phenomenon to pulmonary arterial hypertension (PAH). The potential involvement of the immune system in SSc-associated vascular abnormalities is not clear. Here, we set out to study SSc-related immune parameters and determine whether and which peripheral T cell subsets associate with vascular severity in SSc patients. Peripheral blood and clinical data were collected from 30 SSc patients, 5 patients with idiopathic PAH and 15 age and sex-matched healthy donors (HD). In this cross-sectional cohort, SSc patients with PAH (n = 15) were matched for their age, sex and medication with SSc patients with no signs of PAH (n = 15). Lymphocyte subsets were quantified by multi-colour flow cytometry. SSc patients exhibited elevated percentages of T peripheral helper cells (Tph), CD4+GZMB+ T cells and decreased levels of Th1 cells compared with HD. Increased presence of both CD4+ and CD8+ exhausted-like (CD28−) T cells, characterized by raised cytokine and cytotoxic signature, was also observed in SSc compared with HD blood. Furthermore, IL-4 expressing CD4+CD8+ T cells were significantly increased in SSc peripheral blood. Interestingly, the presence of PAH in SSc was accompanied by a distinct T helper profile, characterized by raised percentages of Th17 and Tph cells. SSc patients with severe vasculopathy (presence of PAH) exhibited a distinct T cell profile, suggesting a potential role of auto-immune inflammation in SSc vascular complications.
- Open Access
- 20 February 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1192-1194
CAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world?
Sander I van Leuven, Raphäel Duivenvoorden; CAR T-Cell therapy in systemic lupus erythematosus and beyond: a brave new world?, Rheumatology, , keae108, https://
- 20 February 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1192-1194
Open AccessCAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world?
Sander I van Leuven, Raphäel Duivenvoorden; CAR T-Cell therapy in systemic lupus erythematosus and beyond: a brave new world?, Rheumatology, , keae108, https://
- 1 August 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (12) , 1638-1639
Are Patients With Systemic Sclerosis Subject to an Increased Risk of Developing Superficial Erosion of Atherosclerotic Plaques?
Various inflammatory rheumatic diseases (RDs) are associated with an increased risk of developing cardiovascular (CV) disease. Increased cardiovascular morbidity and mortality has been reported in inflammatory arthritis (including rheumatoid arthritis, psoriatic arthritis, gout, and spondyloarthritis) and connective tissue disease (including vasculitis, systemic lupus erythematosus, and systemic sclerosis [SSc]).
- 1 August 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (12) , 1638-1639
Are Patients With Systemic Sclerosis Subject to an Increased Risk of Developing Superficial Erosion of Atherosclerotic Plaques?
Various inflammatory rheumatic diseases (RDs) are associated with an increased risk of developing cardiovascular (CV) disease. Increased cardiovascular morbidity and mortality has been reported in inflammatory arthritis (including rheumatoid arthritis, psoriatic arthritis, gout, and spondyloarthritis) and connective tissue disease (including vasculitis, systemic lupus erythematosus, and systemic sclerosis [SSc]).
- Open Access
- 8 July 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (1) , 3-5
Accelerated atherosclerosis in systemic lupus erythematosus: don’t forget the devil we know!
Sander I van Leuven, Amy S Major; Accelerated atherosclerosis in systemic lupus erythematosus: don’t forget the devil we know!, Rheumatology, , kead329, https:/
- 8 July 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (1) , 3-5
Open AccessAccelerated atherosclerosis in systemic lupus erythematosus: don’t forget the devil we know!
Sander I van Leuven, Amy S Major; Accelerated atherosclerosis in systemic lupus erythematosus: don’t forget the devil we know!, Rheumatology, , kead329, https:/